

EUROPEAN HELICOBACTER AND MICROBIOTA STUDY GROUP



**EHMSG – 36th International Workshop on Helicobacter
& Microbiota in Inflammation & Cancer**

September 7–9, 2023
Antwerp, Belgium

Accepted Abstracts

www.microbiotajournal.com

DOI: 10.26355/mhd_20239_857

EUROPEAN HELICOBACTER AND MICROBIOTA STUDY GROUP

PRESIDENT: **Annemieke Smet**, *Belgium*

MEMBERS AND INTERNATIONAL SCIENTIFIC COMMITTEE

Leif P. Andersen, *Denmark*
Emilie Bessède, *France*
Lars Engstrand, *Sweden*
Antonio Gasbarrini, *Italy*
Javier P. Gisbert, *Spain*
Georgina Hold, *Australia*
Gianluca Ianiro, *Italy*
Josbert Keller, *The Netherlands*
Juozas Kupcinskas, *Lithuania*
Marcis Leja, *Latvia*
José C. Machado, *Portugal*
Peter Malfertheiner, *Germany*
Francis Mégraud, *France*
Colm A. O'Morain, *Ireland*
Mirjana Rajilić-Stojanović, *Serbia*
Ari P. Ristimäki, *Finland*
Theodore Rokkas, *Greece*
Christian Schulz, *Germany*
Annemieke Smet, *Belgium*
Herbert Tilg, *Austria*

LOCAL SCIENTIFIC AND ORGANISING COMMITTEE

Annemieke Smet, *Antwerp, Belgium*
Nele Brusselaers, *Antwerp, Belgium*
Heiko De Schepper, *Antwerp, Belgium*
Benedicte De Winter, *Antwerp, Belgium*
Sven Francque, *Antwerp, Belgium*
Marie Joossens, *Ghent, Belgium*
Sébastien Kindt, *Brussels, Belgium*
Sarah Lebeer, *Antwerp, Belgium*
Véronique Yvette Miendje Deyi,
Brussels, Belgium
Philip Plaeke, *Antwerp, Belgium*
Lukas Van Oudenhove, *Leuven, Belgium*

EMERITUS MEMBERS

Anthony Axon, *United Kingdom*
Michel A.L. Deltenre†, *Belgium*
Bram Flahou, *Belgium*
Giovanni Gasbarrini, *Italy*
Alexander M. Hirschl, *Austria*
Pierre Michetti, *Switzerland*
José M. Pajares Garcia†, *Spain*
Ashley B. Price†, *United Kingdom*
Mario G. Quina†, *Portugal*
Erik A.J Rauws, *The Netherlands*
Pentti I. Sipponen, *Finland*
Torkel M. Wadström, *Sweden*

HONORARY MEMBERS

Franco Bazzoli, *Italy*
James G. Fox, *United States*
David Y. Graham, *United States*
Ernst Kuipers, *The Netherlands*
Adrian Lee†, *Australia*
Barry Marshall, *Australia*
Guido N.J. Tytgat, *The Netherlands*

CORRESPONDING FELLOWS

Niyaz Ahmed, *India*
Dmitry Bordin, *Russia*
Luis G. Vaz Coelho, *Brazil*
Hwoon-Yong Jung, *Korea*
Varocha Mahachai, *Thailand*
Yaron Niv, *Israel*
Oleg Shvets, *Ukraine*
Chun-Ying Wu, *Taiwan*
Yoshio Yamaoka, *Japan*
Weicheng You, *China*

TABLE OF CONTENTS

WORKSHOPS	4
– Session 02: News on gastritis	4
– Session 03: Microbiome mechanisms of action (Parallel Session)	6
– Session 04: Helicobacter pylori Genome Project (HpGP)	8
– Session 05: Microbiota modulation for a healthy life	9
– Session 06: Gastric Carcinogenesis (Parallel Session)	11
– Session 07: Microbiota modulation by FMT	13
– Session 09: H. pylori management	15
– Session 10: Diseases & Microbiota	17
<i>Only the abstracts selected to be presented orally in the sessions appear in this programme, and not the abstracts of the invited presentations.</i>	
POSTER	19
– Poster Session 01: Helicobacter 1	19
– Poster Session 02: Helicobacter 2	24
– Poster Session 03: Helicobacter 3	35
– Poster Session 04: Helicobacter 4	46
– Poster Session 05: Helicobacter 5	55
– Poster Session 06: Helicobacter 6	63
– Poster Session 07: Cancer 1	71
– Poster Session 08: Cancer 2	78
– Poster Session 09: Cancer 3	84
– Poster Session 10: Helicobacter 7	90
– Poster Session 11: Helicobacter 8	103
– Poster Session 12: Helicobacter 9	112
– Poster Session 13: Helicobacter 10	122
– Poster Session 14: Helicobacter 11	131
– Poster Session 15: Microbiota 1	143
– Poster Session 16: Microbiota 2	149
– Poster Session 17: Microbiota 3	153
AUTHOR INDEX	160
KEYWORD INDEX	168

Conflict of interest declarations:

In order to help readers form their own judgments of potential bias in published abstracts, authors are asked to declare any competing financial interests.

Contributions of up to EUR 10.000. -(or equivalent value in kind) per year per entity are considered “Modest”. Contributions above EUR 10.000.-per year are considered “Significant”.

Missing abstracts within the consecutive presentation numbers represent withdrawn papers.

S. Oki: B. Research Grant (principal investigator, collaborator or consultant and pending grants as well as grants already received); Significant; Olympus Co., Ltd. **M. Hojo:** C. Other Research Support (supplies, equipment, receipt of drugs or other in-kind support); Significant; Olympus Co., Ltd. **T. Takeda:** C. Other Research Support (supplies, equipment, receipt of drugs or other in-kind support); Significant; Olympus Co., Ltd. **A. Nagahara:** C. Other Research Support (supplies, equipment, receipt of drugs or other in-kind support); Significant; Olympus Co., Ltd.

P04.05

ASSESSMENT OF RISK FACTORS FOR A POSITIVE ¹³C-UREA BREATH TEST IN THE UKRAINIAN POPULATION

S. MELASHCHENKO, I. PALIY, S. ZAIKA, I. CHERNOVA

National Pirogov Memorial Medical University, Vinnytsya, Vinnytsya, Ukraine

Objective: Ukraine remains a country with a high prevalence of *Helicobacter pylori* infection. Our aim was to identify important risk factors for positive ¹³C-UBT as the most accurate diagnosis.

Patients and Methods: The study was conducted from 2006 to 2019 on 972 men (mean age±SD -40.47±14.92) and 1,120 women (age 42.09±15.55) who either never received eradication therapy (1,280 persons) or already received one (control test – 814). The regression analysis was performed by using logistic model (enter method).

Results: 56.7% of primary and 43.3% of control tests were HP-positive. The large number of positive control tests was explained by the passing of the study by individuals who were dissatisfied with the previous results. AUC of logistic model ROC-curve was 0.68 (95%CI 0.657 to 0.701) and percent of cases correctly classified was 64.84 (Table 1).

We found a significantly smaller increase in HP-positive individuals with a large mass – Spearman's coefficient of rank correlation = -0.326 (95%CI -0.391 to -0.257). This could be a suspicion to offer them a larger dose of isotope-labeled urea. However, analysis proved that individuals with increased weight were more likely to have positive results, and these fears are redundant.

Conclusions: We proved a consistent decrease in the prevalence rate of HP-infection in Ukraine (Vinnytsya region as an example). A fact that contradicts most previous studies is the reduced risk of HP-infection among Ukrainian men.

S. Melashchenko: None. I. Paliy: None. S. Zaika: None. I. Chernova: None.

TABLE 1. PARAMETERS OF LOGISTIC REGRESSION ANALYSIS MODEL (ENTER METHOD).

Variable	Coefficient	Std. Error	p	Odds ratio (95% CI)
Primary test -0; Control -1	-1.16951	0.10649	<0.0001	0.3138 (0.2550 to 0.3861)
Year of test (2006-2019)	-0.063577	0.012052	<0.0001	0.9400 (0.9183 to 0.9622)
Body weight (kg)	0.011726	0.0037270	0.0017	1.0118 (1.0044 to 1.0192)
Dyspeptic symptoms (0 or 1)	0.20884	0.22656	0.3567	1.2322 (0.7904 to 1.9211)
Male gender (m=1; f=0)	-0.36776	0.12405	0.0030	0.6940 (0.5443 to 0.8849)
Height (cm)	0.0054344	0.0049702	0.2742	1.0055 (0.9957 to 1.0153)
Age (years)	0.0021307	0.0035866	0.5525	1.0023 (0.9953 to 1.0094)
Constant	126.0764			